Karyopharm Therapeutics Inc. (KPTI)

1,0800 +0,0500 (+4,85%) Al cierre: 04:00PM EDT

Karyopharm Therapeutics Inc.

85 Wells Avenue
Suite 210
Newton, MA 02459-3298
United States
617 658 0600
https://www.karyopharm.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 325

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Richard A. Paulson M.B.A.	President, CEO & Director	1,43M	N/A	1967
Ms. Sohanya Cheng M.B.A.	Executive VP & Chief Commercial Officer	742,95k	N/A	1983
Mr. Stuart Poulton	Executive VP & Chief Development Officer	682,48k	N/A	N/A
Dr. Reshma Rangwala M.D., Ph.D.	Executive VP, Chief Medical Officer & Head of Research	777,32k	N/A	1978
Dr. Mansoor Raza Mirza M.D.	Clinical Consultant, Member of Scientific Advisory Board & Independent Director	150k	N/A	1961
Dr. Sharon Shacham M.B.A., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	1,4M	N/A	1970
Mr. Cameron Peters	Vice President of Finance, Assistant Treasurer & Principal Accounting Officer	N/A	N/A	1960
Ms. Elhan Webb C.F.A.	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Michael J. Mano J.D.	Senior VP, General Counsel & Secretary	625,08k	N/A	1977
Mr. James Accumanno J.D.	Chief Compliance Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Karyopharm Therapeutics Inc., a día 29 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 8; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.